Eden Biodesign Confirms Research Triangle Park Facility
News Jun 26, 2008
Eden Biodesign Ltd. has confirmed its expansion plans for Eden Biodesign, Inc., the Group’s US subsidiary, with the announcement of a facility in the Research Triangle Park, North Carolina.
Building on the strong track record and recent growth of its UK cGMP facility, Eden Biodesign, Inc., will offer a range of cell line/strain development and early process development services.
Eden Biodesign provides services in support of all major biopharmaceutical production technologies (mammalian, microbial and viral) and offers a “toolbox” of expression technologies, some via collaboration with partner companies.
“The selection of North Carolina’s world-renowned Research Triangle Park signifies the strategic importance of the North American market to Eden Biodesign”, said Dr. Crawford Brown, Chief Executive Officer, Eden Biodesign. “By establishing a subsidiary in the United States we are making it easier for clients to access Eden’s proven expertise and inspected cGMP manufacturing facilities and confirming Eden’s position as a recognized global player in the contract biopharmaceutical manufacturing services market”.
Eden Biodesign is further cementing its commitment to the North American market with the recent appointment of Michael Faughnan as Business Development Director, who will be supporting the Company’s expansion into the North American market from Southern California. The Company is actively developing technology and marketing collaborations with industry leaders throughout North America.
New Chemical Synthesis Process: Synergy of Two Catalysts in One FlaskNews
Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.READ MORE
Synthesis of Drug-Like Molecules Simplified Using New Cross-Coupling MethodNews
Researchers have designed a new molecule-building method. The technique, described recently in the journal Science, paves the way toward other new chemical reactions and facilitates the synthesis of pharmaceutically-relevant molecules.READ MORE
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018
10th International Conference on Mass Spectrometry and Chromatography
Oct 08 - Oct 09, 2018